Ibr, Bvd Type I & Ii, Pi3, Brsv, Mlv Mannheimia Haemolytica Toxoid
10 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
8
Deaths Reported
8000.0%
Death Rate
Active Ingredients
Ibr, Bvd Type I & Ii, Pi3, Brsv, Mlv Mannheimia Haemolytica Toxoid
Administration Routes
SubcutaneousUnknown
Species Affected
Cattle 10
Most Affected Breeds
Cattle (unknown) 5
Cattle (other) 2
Holstein-Friesian also known as Holstein 1
Aberdeen Angus 1
Crossbred Bovine/Cattle 1
Most Reported Reactions
Death 7
Partial lack of efficacy 3
Diarrhoea 2
Anorexia 2
Nasal discharge 2
Respiratory tract infection NOS 1
Keratoconjunctivitis 1
Increased respiratory rate 1
Rhinitis 1
Weight loss 1
INEFFECTIVE, PARASITE(S) NOS 1
Anaphylaxis 1
Outcome Breakdown
Died
8 (44.4%)
Outcome Unknown
4 (22.2%)
Recovered/Normal
3 (16.7%)
Ongoing
2 (11.1%)
Recovered with Sequela
1 (5.6%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.